Citadel Advisors
KPTI icon

Citadel Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

Citadel Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-31,709
Closed -$242K – 13643
2025
Q4 		$233K Buy
+31,709
New +$194K ﹤0.01% 10702
2025
Q3 		– Sell
-206,781
Closed -$1.11M – 13496
2025
Q2 		$891K Sell
206,781
-128
-0.1% -$628 ﹤0.01% 7363
2025
Q1 		$774K Sell
206,909
-2
-0% -$17 ﹤0.01% 7523
2024
Q4 		$2.1M Hold
206,911
– – ﹤0.01% 5517
2024
Q3 		$2.58M Buy
206,911
+151
+0.1% +$1.88K ﹤0.01% 5048
2024
Q2 		$2.69M Sell
206,760
-245
-0.1% -$4.06K ﹤0.01% 4768
2024
Q1 		$4.69M Buy
207,005
+245
+0.1% +$4.3K ﹤0.01% 4044
2023
Q4 		$2.68M Sell
206,760
-166
-0.1% -$2.24K ﹤0.01% 4847
2023
Q3 		$4.16M Sell
206,926
-3,053
-1% -$68.5K ﹤0.01% 3958
2023
Q2 		$5.64M Sell
209,979
-30,185
-13% -$1.3M ﹤0.01% 3464
2023
Q1 		$14M Sell
240,164
-7,380
-3% -$364K ﹤0.01% 2358
2022
Q4 		$12.3M Buy
247,544
+126,901
+105% +$8.8M ﹤0.01% 2532
2022
Q3 		$9.88M Buy
120,643
+93,420
+343% +$6.98M ﹤0.01% 2788
2022
Q2 		$1.84M Sell
27,223
-29,745
-52% -$2.73M ﹤0.01% 5699
2022
Q1 		$6.3M Buy
56,968
+41,709
+273% +$5.2M ﹤0.01% 3735
2021
Q4 		$1.47M Buy
15,259
+541
+4% +$53.9K ﹤0.01% 6928
2021
Q3 		$1.28M Buy
14,718
+645
+5% +$67K ﹤0.01% 7485
2021
Q2 		$2.18M Sell
14,073
-40,761
-74% -$5.92M ﹤0.01% 6383
2021
Q1 		$8.65M Buy
54,834
+36,362
+197% +$7.66M ﹤0.01% 3201
2020
Q4 		$4.29M Sell
18,472
-43,357
-70% -$10M ﹤0.01% 3934
2020
Q3 		$13.5M Buy
61,829
+52,554
+567% +$12.9M ﹤0.01% 1945
2020
Q2 		$2.63M Sell
9,275
-91,145
-91% -$27M ﹤0.01% 4089
2020
Q1 		$28.9M Buy
100,420
+7,554
+8% +$2.08M 0.01% 957
2019
Q4 		$26.7M Sell
92,866
-9,173
-9% -$1.99M 0.01% 1227
2019
Q3 		$14.7M Buy
102,039
+43,310
+74% +$5.87M 0.01% 1774
2019
Q2 		$5.28M Sell
58,729
-60,765
-51% -$4.88M ﹤0.01% 3008
2019
Q1 		$10.5M Buy
119,494
+102,689
+611% +$11.4M 0.01% 2011
2018
Q4 		$2.36M Buy
16,805
+731
+5% +$123K ﹤0.01% 3887
2018
Q3 		$4.11M Buy
16,074
+4,317
+37% +$1.19M ﹤0.01% 3252
2018
Q2 		$3M Buy
11,757
+5,494
+88% +$1.36M ﹤0.01% 3482
2018
Q1 		$1.26M Buy
6,263
+2,642
+73% +$527K ﹤0.01% 4454
2017
Q4 		$521K Buy
3,621
+2,286
+171% +$367K ﹤0.01% 5587
2017
Q3 		$220K Sell
1,335
-2,741
-67% -$393K ﹤0.01% 6552
2017
Q2 		$553K Sell
4,076
-1,239
-23% -$183K ﹤0.01% 4973
2017
Q1 		$1.02M Buy
5,315
+2,249
+73% +$361K ﹤0.01% 3959
2016
Q4 		$432K Buy
3,066
+1,109
+57% +$150K ﹤0.01% 5135
2016
Q3 		$286K Buy
+1,957
New +$235K ﹤0.01% 5744
2016
Q1 		– Sell
-1,524
Closed -$168K – 7395
2015
Q4 		$303K Sell
1,524
-37,039
-96% -$8.02M ﹤0.01% 5197
2015
Q3 		$6.09M Buy
38,563
+8,346
+28% +$2.23M 0.01% 1746
2015
Q2 		$12.3M Buy
30,217
+28,519
+1,680% +$12.3M 0.01% 1329
2015
Q1 		$779K Buy
1,698
+1,679
+8,837% +$724K ﹤0.01% 4278
2014
Q4 		$11K Buy
+19
New +$10.8K ﹤0.01% 8101
2014
Q3 		– Sell
-5,260
Closed -$2.97M – 8270
2014
Q2 		$3.67M Buy
+5,260
New +$2.45M ﹤0.01% 2118

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Citadel Advisors's KPTI Position: Q1 2026 in Review

Citadel Advisors sold out of Karyopharm Therapeutics (KPTI) in Q1 2026, closing a stake of 31,709 shares — an estimated $242K sold.

Citadel Advisors first reported a position in KPTI in Q2 2014 and held it in 43 quarters. The position peaked at $28.9M in Q1 2020. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Citadel Advisors reported no remaining Karyopharm Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 31,709 Karyopharm Therapeutics shares in Q1 2026, an estimated $242K.
  • Citadel Advisors first reported a position in Karyopharm Therapeutics in Q2 2014 and held it in 43 quarters.
  • Citadel Advisors's Karyopharm Therapeutics position peaked at $28.9M in Q1 2020.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.